Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dasotraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | MLNR | O43193 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmethylsertraline SCHEMBL29737233 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29481074 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4781834 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL263132 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL9611184 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Dasotraline SCHEMBL263142 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL260449 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL4570539 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL259292 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Desmethylsertraline SCHEMBL29757858 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| WO-2024107708-A1 | TAAR RECEPTOR AGONISTS FOR SEXUAL DYSFUNCTION | ReJoy (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2024-04-11 | — | — | US | disclosed |
| WO-2022223612-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | NUVAMID SA (CH) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022223613-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2022-10-27 | — | — | WO | disclosed |
| EP-4079311-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | Nuvamid SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-4079310-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES | Nuvamid SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| US-11383084-B2 | Treatment of dermatological conditions via neuromodulation | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-11337937-B2 | TARR receptor agonists for sexual dysfunction | JOHN MCCOY | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | SNCA, NLN, PARK7 | SLC6A2 134/4885SLC6A4 401/4885SLC6A3 115/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | SLC6A2 138/4885SLC6A4 397/4885SLC6A3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.